

**Amendments to the Claims:**


This listing of claims will replace all prior versions, and listings, of claims in the application:

**Listing of Claims:**

1. (Previously presented) A compound of the general formula I:



or pharmaceutically acceptable salt thereof, wherein V is a non-peptidic vector having affinity for the Angiotensin II receptor and is selected from Losartan, Valsartan, Candesartan and Eprosartan, L is a bond, a spacer or a linker moiety, and Z represents a chelating agent of Formula e carrying an imageable moiety of a metallic radionuclide M



e

2. (Cancelled)




3. (Cancelled)




4. (Cancelled)

5. (Cancelled)

6. (Cancelled)
7. (Previously presented) A pharmaceutical composition comprising an effective amount of a compound of claim 1 or a salt thereof, together with one or more pharmaceutically acceptable adjuvants, excipients or diluents for use in enhancing image contrast in *in vivo* imaging or for treatment of a disease.
8. (Cancelled)
9. (Previously presented) A method of generating images of a human or animal body involving administering a contrast agent to said body, and generating an image of at least a part of said body to which said contrast agent has distributed, characterised in that said contrast agent comprises a compound as claimed in claim 1.
10. (Previously presented) A method of generating enhanced images of a human or animal body previously administered with a contrast agent composition comprising a compound as claimed in claim 1, which method comprises generating an image of at least part of said body.
11. (Previously presented) A compound as claimed in claim 1, wherein M comprises  $^{67}\text{Ga}$ ,  $^{111}\text{In}$ ,  $^{81\text{m}}\text{Kr}$ ,  $^{99}\text{Mo}$ ,  $^{99\text{m}}\text{Tc}$  and  $^{201}\text{Tl}$ .

12. (Currently amended) Compounds as claimed in claim 1 being Tc chelates of compounds of the formulas





▲